A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
Status:
Completed
Trial end date:
2020-04-20
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and tolerability of SEP363856 in subjects with Parkinson's
Disease Psychosis. This study is accepting male and female participants 55 years of age and
older who have been diagnosed with Parkinson's Disease. This study will be conducted in 24
study centers in the United States. The study will last approximately 21 weeks